In addition, two PARP inhibitors, olaparib and rucaparib, received US FDA designation for metastatic castration‐resistant prostate cancer with homologous recombination repair gene mutation or BRCA mutation or ATM mutation.494, 495. Here, PARP1 is linked to Familial prostate cancer.